Literature DB >> 18338267

Preoperative assessment for pituitary surgery.

Olivia Pereira1, John S Bevan.   

Abstract

Evaluation of pituitary function is essential before pituitary surgery. In hyperprolactinaemic patients with a pituitary macrolesion, tumoral secretion of prolactin must be distinguished from 'disconnection' hyperprolactinaemia; serum prolactin >200 mcg/l is virtually diagnostic of a macroprolactinoma whereas levels <80 mcg/l usually indicate 'disconnection'. The prolactin 'hook effect' should be excluded. A minimum set of pre-operative endocrine tests should include serum electrolytes, cortisol (at 08.00-09.00 h), free-T4, TSH, prolactin, oestradiol/testosterone, LH, FSH and IGF-1. Some clinicians will choose to perform pre-operative Synacthen or insulin tolerance testing to further define ACTH reserve. If basal cortisol, Synacthen or insulin tolerance test results are abnormal, steroid supplementation is indicated for at least the first 48 h after surgery. If pre-operative basal cortisol is <100 nmol/l, replacement steroids should be continued until the time of post-operative pituitary function testing (6-8 weeks after surgery). In patients with pre-operative basal cortisol >450 nmol/l, peri-operative glucocorticoid replacement is unnecessary and further cortisol levels should be checked a few days after surgery. Most clinicians defer detailed evaluation of growth hormone reserve until after surgery. Diabetes insipidus is rarely a problem before surgery in patients with pituitary adenomas but may occur post-operatively. Close co-operation between anesthetic, endocrine and surgical teams is strongly recommended.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18338267     DOI: 10.1007/s11102-008-0093-7

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  21 in total

1.  Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis.

Authors:  Annice Mukherjee; Robert D Murray; Breeda Columb; Helena K Gleeson; Stephen M Shalet
Journal:  Clin Endocrinol (Oxf)       Date:  2003-12       Impact factor: 3.478

2.  High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas.

Authors:  E St-Jean; F Blain; R Comtois
Journal:  Clin Endocrinol (Oxf)       Date:  1996-03       Impact factor: 3.478

Review 3.  Clinical utility of measurements of insulin-like growth factor 1.

Authors:  David R Clemmons
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2006-08

4.  Comparison of tests of stress-released cortisol secretion in pituitary disease.

Authors:  S M Orme; S R Peacey; J H Barth; P E Belchetz
Journal:  Clin Endocrinol (Oxf)       Date:  1996-08       Impact factor: 3.478

5.  Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.

Authors:  Niki Karavitaki; Gaya Thanabalasingham; Helena C A Shore; Raluca Trifanescu; Olaf Ansorge; Niki Meston; Helen E Turner; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

Review 6.  Macroprolactin; high molecular mass forms of circulating prolactin.

Authors:  M N Fahie-Wilson; R John; A R Ellis
Journal:  Ann Clin Biochem       Date:  2005-05       Impact factor: 2.057

7.  Dopamine agonists and pituitary tumor shrinkage.

Authors:  J S Bevan; J Webster; C W Burke; M F Scanlon
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

8.  The relationship between serum prolactin and immunocytochemical staining for prolactin in patients with pituitary macroadenomas.

Authors:  R J Ross; A Grossman; P Bouloux; L H Rees; I Doniach; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1985-09       Impact factor: 3.478

Review 9.  Glucocorticoid replacement in pituitary surgery: guidelines for perioperative assessment and management.

Authors:  Warrick J Inder; Penny J Hunt
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

10.  The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism.

Authors:  A A Toogood; C G Beardwell; S M Shalet
Journal:  Clin Endocrinol (Oxf)       Date:  1994-10       Impact factor: 3.478

View more
  1 in total

1.  Selective use of peri-operative steroids in pituitary tumor surgery: escape from dogma.

Authors:  Jacqueline Regan; Joseph Watson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-18       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.